166 related articles for article (PubMed ID: 31104010)
21. Usefulness of plasma HGF level for monitoring acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer.
Umeguchi H; Sueoka-Aragane N; Kobayashi N; Nakamura T; Sato A; Takeda Y; Hayashi S; Sueoka E; Kimura S
Oncol Rep; 2015 Jan; 33(1):391-6. PubMed ID: 25338771
[TBL] [Abstract][Full Text] [Related]
22. Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer.
Yamada T; Takeuchi S; Kita K; Bando H; Nakamura T; Matsumoto K; Yano S
J Thorac Oncol; 2012 Feb; 7(2):272-80. PubMed ID: 22089117
[TBL] [Abstract][Full Text] [Related]
23. Soluble c-Met expression in the peritoneal fluid and serum of patients with different stages of endometriosis.
KhoshdelRad N; Salehi Z; Mashayekhi F; Abbasi O; Mirzajani E
Arch Gynecol Obstet; 2014 May; 289(5):1107-12. PubMed ID: 24213016
[TBL] [Abstract][Full Text] [Related]
24. [Study on the prognostic value of hepatocyte growth factor and c-met for patients with hepatocellular carcinoma].
Wu FS; Zheng SS; Wu LJ; Ding W; Ma ZM; Wang ZM; Teng LS; Zhao WH
Zhonghua Wai Ke Za Zhi; 2006 May; 44(9):603-8. PubMed ID: 16784653
[TBL] [Abstract][Full Text] [Related]
25. A HGF/cMET autocrine loop is operative in multiple myeloma bone marrow endothelial cells and may represent a novel therapeutic target.
Ferrucci A; Moschetta M; Frassanito MA; Berardi S; Catacchio I; Ria R; Racanelli V; Caivano A; Solimando AG; Vergara D; Maffia M; Latorre D; Rizzello A; Zito A; Ditonno P; Maiorano E; Ribatti D; Vacca A
Clin Cancer Res; 2014 Nov; 20(22):5796-807. PubMed ID: 25212607
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET.
Zhou JY; Chen X; Zhao J; Bao Z; Chen X; Zhang P; Liu ZF; Zhou JY
Cancer Lett; 2014 Sep; 351(2):265-71. PubMed ID: 24983493
[TBL] [Abstract][Full Text] [Related]
27. The Therapeutic Potential of Targeting the HGF/cMET Axis in Ovarian Cancer.
Moran-Jones K
Mol Diagn Ther; 2016 Jun; 20(3):199-212. PubMed ID: 27139908
[TBL] [Abstract][Full Text] [Related]
28. Over-expression of hepatocyte growth factor/scatter factor (HGF/SF) and the HGF/SF receptor (cMET) are associated with a high risk of metastasis and recurrence for children and young adults with papillary thyroid carcinoma.
Ramirez R; Hsu D; Patel A; Fenton C; Dinauer C; Tuttle RM; Francis GL
Clin Endocrinol (Oxf); 2000 Nov; 53(5):635-44. PubMed ID: 11106926
[TBL] [Abstract][Full Text] [Related]
29. Predictive blood plasma biomarkers for EGFR inhibitor-induced skin rash.
Hichert V; Scholl C; Steffens M; Paul T; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seufferlein T; Stingl J
Oncotarget; 2017 May; 8(21):35193-35204. PubMed ID: 28456787
[TBL] [Abstract][Full Text] [Related]
30. Tyrosylprotein sulfotransferase 1 expression is negatively correlated with c‑Met and lymph node metastasis in human lung cancer.
Jiang Z; Zhu J; Ma Y; Hong C; Xiao S; Jin L
Mol Med Rep; 2015 Oct; 12(4):5217-22. PubMed ID: 26238632
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of serum HGF and CK18 levels in patients with esophageal cancer.
Kilic-Baygutalp N; Ozturk N; Orsal-Ibisoglu E; Gündogdu B; Ozgeris FB; Bakan N; Bakan E; Kilic AF
Genet Mol Res; 2016 Aug; 15(3):. PubMed ID: 27706656
[TBL] [Abstract][Full Text] [Related]
32. Higher cMET dependence of sacral compared to clival chordoma cells: contributing to a better understanding of cMET in chordoma.
Lohberger B; Scheipl S; Heitzer E; Quehenberger F; de Jong D; Szuhai K; Liegl-Atzwanger B; Rinner B
Sci Rep; 2021 Jun; 11(1):12466. PubMed ID: 34127734
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA‑200a suppresses migration and invasion and enhances the radiosensitivity of NSCLC cells by inhibiting the HGF/c‑Met signaling pathway.
Du M; Wang J; Chen H; Wang S; Chen L; Xu Y; Su F; Lu X
Oncol Rep; 2019 Mar; 41(3):1497-1508. PubMed ID: 30569179
[TBL] [Abstract][Full Text] [Related]
34. Functional expression of HGF and its receptor in human colorectal cancer.
Otte JM; Schmitz F; Kiehne K; Stechele HU; Banasiewicz T; Krokowicz P; Nakamura T; Fölsch UR; Herzig K
Digestion; 2000; 61(4):237-46. PubMed ID: 10878450
[TBL] [Abstract][Full Text] [Related]
35. Human epidermal growth factor receptor 2, epidermal growth factor receptor, and c-MET overexpression and survival in biliary tract cancer: A meta-analysis.
Zhou W; Jiang C; Zhan N; Lv X; Fan L; Ninu M
J Cancer Res Ther; 2018; 14(Supplement):S28-S35. PubMed ID: 29578146
[TBL] [Abstract][Full Text] [Related]
36. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
37. Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type EGFR.
Yang H; Wang R; Peng S; Chen L; Li Q; Wang W
Oncotarget; 2016 Mar; 7(13):16273-81. PubMed ID: 26919104
[TBL] [Abstract][Full Text] [Related]
38. Epidermal growth factor and hepatocyte growth factor cooperate to enhance cell proliferation, scatter, and invasion in murine mammary epithelial cells.
Accornero P; Miretti S; Starvaggi Cucuzza L; Martignani E; Baratta M
J Mol Endocrinol; 2010 Feb; 44(2):115-25. PubMed ID: 19850646
[TBL] [Abstract][Full Text] [Related]
39. Association between plasma hepatocyte growth factor and gefitinib resistance in patients with advanced non-small cell lung cancer.
Han JY; Kim JY; Lee SH; Yoo NJ; Choi BG
Lung Cancer; 2011 Nov; 74(2):293-9. PubMed ID: 21440951
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of circulating c-met messenger RNA is significantly correlated with nodal stage and early recurrence in non-small cell lung cancer.
Cheng TL; Chang MY; Huang SY; Sheu CC; Kao EL; Cheng YJ; Chong IW
Chest; 2005 Sep; 128(3):1453-60. PubMed ID: 16162743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
